Valuation: CSL Limited

Market Cap 58.38B 49.98B 46.63B 42.79B 80.41B 5,586B 81.99B 553B 216B 2,799B 219B 214B 9,268B P/E 2027 *
20.1x
P/E 2028 * 18.2x
Enterprise Value 67.51B 57.8B 53.93B 49.48B 92.98B 6,459B 94.81B 640B 249B 3,237B 253B 248B 10,717B EV / Sales 2027 *
4.3x
EV / Sales 2028 * 4.13x
Free-Float
99.97%
Yield 2027 *
2.46%
Yield 2028 * 2.61%
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%+3.38%+40.98%-1.32% 83.96B
-24.62%+103.79%+382.39%+16.78% 69.62B
+2.84%+23.66%-24.08%-36.73% 56.76B
+1.94%+1.61%-0.03%+32.78% 51.35B
+0.05%-0.55%+11.63%+167.36% 48.41B
-2.14%+3.09%+56.24%-18.07% 32.74B
-0.14%+6.23%+48.52%+97.33% 26.04B
+3.00%+5.91%+3.53%+221.78% 21.81B
-0.90%+2.85%+62.35%+124.85% 17.11B
Average -2.31%+24.26%+64.61%+67.19% 45.31B
Weighted average by Cap. -3.79%+34.72%+82.16%+43.34%

Financials

2027 *2028 *
Net sales 15.7B 13.44B 12.54B 11.51B 21.63B 1,502B 22.05B 149B 58B 753B 58.95B 57.67B 2,493B 16.23B 13.9B 12.97B 11.9B 22.36B 1,553B 22.8B 154B 59.97B 778B 60.95B 59.62B 2,577B
Net income 2.82B 2.41B 2.25B 2.07B 3.88B 270B 3.96B 26.71B 10.41B 135B 10.58B 10.35B 447B 3.16B 2.7B 2.52B 2.31B 4.35B 302B 4.43B 29.91B 11.66B 151B 11.85B 11.59B 501B
Net Debt 9.13B 7.82B 7.29B 6.69B 12.57B 874B 12.82B 86.52B 33.73B 438B 34.28B 33.53B 1,449B 8.73B 7.48B 6.98B 6.4B 12.03B 836B 12.26B 82.75B 32.26B 419B 32.79B 32.07B 1,386B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-